ApicHope Pharmaceutical announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has developed the Innovative Drug APH1727 tablet, which has been approved by the FDA in the USA to conduct clinical trials within the country. APH1727 tablet is a highly active and highly selective glucagon-like peptide-1 receptor agonist intended for the treatment of type 2 diabetes. This Pharmaceutical has not yet been approved for sale domestically or abroad.
一品红：创新药APH1727片获美国FDA临床试验批准
ApicHope Pharmaceutical: The Innovative Drug APH1727 tablet has been approved for clinical trials by the FDA in the USA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.